OPQ’s 2022 Report Shows the Global Task of Ensuring Quality
FDA Law Blog
JULY 18, 2023
Those include biological products licensed under Biologics License Applications (BLAs), approved drugs under New Drug Applications (NDAs), and generic products under approved Abbreviated New Drug Applications (ANDAs). CGMP deviations caused 56 recalls, and excipient manufacturers performed 51 recalls due to contamination.
Let's personalize your content